Genomic Landscape of Lung Cancer in the Young

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 20

PMID 36263208

Authors

Rossana Ruiz

Marco Galvez-Nino

Katia Roque

Jaime Montes

Maria Nunez

Luis Raez

Sergio Sanchez-Gambetta

Sandra Jauregui

Sandra Viale

Edward S Smith

Joseph A Pinto

Luis Mas

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer in the young is a rare entity of great interest due to the high frequency of targetable mutations. In this study, we explored the genomic landscape of non-small cell lung cancer (NSCLC) in young patients and compared it with genetic alterations in older patients.

Methods: Comparative study of the genomic profile of NSCLC young (≤40 years old) vs older patients (>40 years old) from Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima, Peru. Archival paraffin-embedded tumor samples were profiled with FoundationOne CDx assay to identify short variants alterations (insertions and deletions), copy number variations (CNV), tumor mutational burden and microsatellite instability in 324 driver genes and rearrangements in 28 commonly rearranged genes. A targetable alteration was defined as any alteration in a driver oncogene for which an FDA approved therapy existed at the time of study enrollment.

Results: Overall, 62 tumors were profiled, 32 from young and 30 from older patients. All clinicopathological features (smoking status, clinical stage, and histology) were similar between groups, except for gender (65.6% of females in the younger group vs 40% in the older group, P=0.043). At least one actionable mutation was present in 84.4% and 83.3% in younger and older patients, respectively. Alteration rates in the main genes were: BRAF, 3.1%(n=1) vs 0%; EGFR, 46.9% (n=15) vs 43.3% (n=13); ERBB2, 12.5% (n=4) vs 16.7% (n=5); KRAS, 15.6% (n=5) vs 16.7% (n=5); ALK, 6.3% (n=2) vs 3.3% (n=1); RET, 0.0% vs 3.3% (n=1); ROS1, 3.1% (n=1) vs 3.3% (n=1); NTRK1, 0.0% vs 3.3% (n=1) and MET, 3.1% (n=1) vs 13.3% (n=4). Mean TMB was 4.04 Mut/Mb (SD ± 3.98) for young vs 8.06 Mut/Mb (SD ± 9.84) for older patients (P=0.016). There were not significant differences in CNV, frequency of gene rearrangements, or microsatellites instability.

Conclusion: NSCLC in the young in our cohort was characterized by a high frequency of actionable genetic aberrations and a low TMB, which was also true for our older patients. The enrichment of actionable mutations in young patients described in other reports might be attributed to differences in the etiology and clinicopathological characteristics between younger and older patients and therefore not be applicable to all populations.

Citing Articles

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.

Wallen Z, Ko H, Nesline M, Hastings S, Strickland K, Previs R Front Immunol. 2024; 15:1413956.

PMID: 38975340 PMC: 11224431. DOI: 10.3389/fimmu.2024.1413956.

References

Corrales-Rodriguez L, Arrieta O, Mas L, Baez-Saldana R, Castillo-Fernandez O, Blais N . An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017; 113:30-36. DOI: 10.1016/j.lungcan.2017.08.022. View

Hernandez-Pedro N, Soca-Chafre G, Alaez-Verson C, Carrillo-Sanchez K, Aviles-Salas A, Vergara E . Mutational profile by targeted next generation sequencing of non-small cell lung cancer in the Mexican population. Salud Publica Mex. 2019; 61(3):308-317. DOI: 10.21149/10113. View

Suidan A, Roisman L, Belilovski Rozenblum A, Ilouze M, Dudnik E, Zer A . Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. J Glob Oncol. 2019; 5:1-8. PMC: 6550091. DOI: 10.1200/JGO.18.00216. View

Pan X, Lv T, Zhang F, Fan H, Liu H, Song Y . Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger. Clin Transl Oncol. 2018; 20(9):1168-1174. DOI: 10.1007/s12094-018-1838-z. View

Galvez-Nino M, Ruiz R, Pinto J, Roque K, Mantilla R, Raez L . Lung Cancer in the Young. Lung. 2019; 198(1):195-200. DOI: 10.1007/s00408-019-00294-5. View

Cai L, Chen Y, Tong X, Wu X, Bao H, Shao Y . The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients. Int J Cancer. 2021; . DOI: 10.1002/ijc.33583. View

Dela Cruz C, Tanoue L, Matthay R . Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4):605-44. PMC: 3864624. DOI: 10.1016/j.ccm.2011.09.001. View

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

Willis C, Fiander M, Tran D, Korytowsky B, Thomas J, Calderon F . Tumor mutational burden in lung cancer: a systematic literature review. Oncotarget. 2019; 10(61):6604-6622. PMC: 6859921. DOI: 10.18632/oncotarget.27287. View

10.

Jiao X, Qin B, You P, Cai J, Zang Y . The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 2018; 123:70-75. DOI: 10.1016/j.lungcan.2018.07.003. View

11.

Donner I, Katainen R, Sipila L, Aavikko M, Pukkala E, Aaltonen L . Germline mutations in young non-smoking women with lung adenocarcinoma. Lung Cancer. 2018; 122:76-82. DOI: 10.1016/j.lungcan.2018.05.027. View

12.

Jemal A, Miller K, Ma J, Siegel R, Fedewa S, Islami F . Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. N Engl J Med. 2018; 378(21):1999-2009. PMC: 7717174. DOI: 10.1056/NEJMoa1715907. View

13.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li B . Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers. Clin Cancer Res. 2018; 25(3):1063-1069. PMC: 6347551. DOI: 10.1158/1078-0432.CCR-18-1102. View

14.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

15.

Sacher A, Dahlberg S, Heng J, Mach S, Janne P, Oxnard G . Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016; 2(3):313-20. PMC: 4819418. DOI: 10.1001/jamaoncol.2015.4482. View

16.

Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner A, Nag A, Watson J . Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov. 2020; 11(3):591-598. PMC: 7933062. DOI: 10.1158/2159-8290.CD-20-1165. View

17.

Levy D, Chaloupka F, Gitchell J . The effects of tobacco control policies on smoking rates: a tobacco control scorecard. J Public Health Manag Pract. 2004; 10(4):338-53. DOI: 10.1097/00124784-200407000-00011. View

18.

Skidmore Z, Wagner A, Lesurf R, Campbell K, Kunisaki J, Griffith O . GenVisR: Genomic Visualizations in R. Bioinformatics. 2016; 32(19):3012-4. PMC: 5039916. DOI: 10.1093/bioinformatics/btw325. View

19.

Chen X, Xu B, Li Q, Xu X, Li X, You X . Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua. Mol Genet Genomic Med. 2020; 8(9):e1398. PMC: 7507563. DOI: 10.1002/mgg3.1398. View

20.

Ruiz R, Galvez-Nino M, Poquioma E, Limache-Garcia A, Amorin E, Olivera M . Lung Cancer in Peru. J Thorac Oncol. 2020; 15(6):891-898. DOI: 10.1016/j.jtho.2020.01.018. View